The 5HTTLPR polymorphism, psychopathologic symptoms, and platelet [3H-] paroxetine binding in bulimic syndromes
Article first published online: 22 DEC 2004
Copyright © 2004 Wiley Periodicals, Inc.
International Journal of Eating Disorders
Volume 37, Issue 1, pages 57–60, January 2005
How to Cite
Steiger, H., Joober, R., Israël, M., Young, S. N., Ng Ying Kin, N. M. K., Gauvin, L., Bruce, K. R., Joncas, J. and Torkaman-Zehi, A. (2005), The 5HTTLPR polymorphism, psychopathologic symptoms, and platelet [3H-] paroxetine binding in bulimic syndromes. Int. J. Eat. Disord., 37: 57–60. doi: 10.1002/eat.20073
- Issue published online: 22 DEC 2004
- Article first published online: 22 DEC 2004
- Manuscript Accepted: 5 JAN 2004
- 5HTTLPR polymorphism;
- psychopathologic symptoms;
- bulimic syndromes
A short (s) allele in the promoter region of the 5-hydroxytryptamine (5-HT) transporter gene (5HTTLPR) has been associated with low transcription of the 5-HT transporter protein, and with clinical manifestations including impulsivity, affective disorder, and bulimia nervosa.
We studied implications of the 5HTTLPR s allele for eating symptoms, psychopathologic traits, and platelet [3H-] paroxetine binding in 59 women with bulimia spectrum syndromes.
Compared with those without it, carriers of the s allele of 5HTTLPR showed significantly more affective instability, behavioral impulsivity, interpersonal insecurity, comorbid borderline personality disorder (BPD), and lower density (Bmax) of paroxetine-binding sites.
Our results suggest that proneness to impulsivity, affective dysregulation, and reduced central 5-HT reuptake may (in part) be codetermined by the 5HTTLPR polymorphism. However, given inconsistent 5HTTLPR expression in different populations, we speculate that we may be observing a phenotype (i.e., eating disorder)-dependent manifestation. © 2004 by Wiley Periodicals, Inc.